## Alexey A Belogurov Jr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3369493/publications.pdf

Version: 2024-02-01

82 papers

1,609 citations

361045 20 h-index 37 g-index

88 all docs 88 docs citations

88 times ranked 1955 citing authors

#	Article	IF	Citations
1	Microfluidic droplet platform for ultrahigh-throughput single-cell screening of biodiversity.  Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2550-2555.	3.3	182
2	Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 281-286.	3.3	175
3	Recognition and Degradation of Myelin Basic Protein Peptides by Serum Autoantibodies: Novel Biomarker for Multiple Sclerosis. Journal of Immunology, 2008, 180, 1258-1267.	0.4	111
4	Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1243-1248.	3.3	79
5	Combinatorial antibody library from multiple sclerosis patients reveals antibodies that crossâ€react with myelin basic protein and EBV antigen. FASEB Journal, 2011, 25, 4211-4221.	0.2	70
6	Liposomeâ€encapsulated peptides protect against experimental allergic encephalitis. FASEB Journal, 2013, 27, 222-231.	0.2	55
7	<i>Reactibodies</i> generated by kinetic selection couple chemical reactivity with favorable protein dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15954-15959.	3.3	48
8	Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunology Letters, 2006, 103, 45-50.	1.1	47
9	Design of Targeted B Cell Killing Agents. PLoS ONE, 2011, 6, e20991.	1.1	41
10	Ubiquitinâ€independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity. FASEB Journal, 2015, 29, 1901-1913.	0.2	39
11	The Pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and Immunological Profiling of Physiological Fluids. Molecular and Cellular Proteomics, 2016, 15, 2366-2378.	2.5	39
12	Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde. BioEssays, 2009, 31, 1161-1171.	1.2	38
13	Multiple Sclerosis Autoantigen Myelin Basic Protein Escapes Control by Ubiquitination during Proteasomal Degradation. Journal of Biological Chemistry, 2014, 289, 17758-17766.	1.6	31
14	Noggin4 is a long-range inhibitor of Wnt8 signalling that regulates head development in Xenopus laevis. Scientific Reports, 2016, 6, 23049.	1.6	31
15	CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study. Neurotherapeutics, 2016, 13, 895-904.	2.1	30
16	A novel expression cassette delivers efficient production of exclusively tetrameric human butyrylcholinesterase with improved pharmacokinetics for protection against organophosphate poisoning. Biochimie, 2015, 118, 51-59.	1.3	25
17	Strategies for the selection of catalytic antibodies against organophosphorus nerve agents. Chemico-Biological Interactions, 2013, 203, 196-201.	1.7	24
18	Heavy–light chain interrelations of MS-associated immunoglobulins probed by deep sequencing and rational variation. Molecular Immunology, 2014, 62, 305-314.	1.0	23

#	Article	IF	Citations
19	Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF- $\langle i \rangle$ 1± $\langle i \rangle$ 2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients. Mediators of Inflammation, 2016, 2016, 1-8.	1.4	23
20	Role of κâ†'λ light-chain constant-domain switch in the structure and functionality of A17 reactibody. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 708-719.	2.5	22
21	Exposure to the Epstein–Barr Viral Antigen Latent Membrane Protein 1 Induces Myelin-Reactive Antibodies In Vivo. Frontiers in Immunology, 2017, 8, 777.	2.2	22
22	The Transcriptome of Type I Murine Astrocytes under Interferon-Gamma Exposure and Remyelination Stimulus. Molecules, 2017, 22, 808.	1.7	21
23	Proteasome: a Nanomachinery of Creative Destruction. Biochemistry (Moscow), 2019, 84, 159-192.	0.7	20
24	Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma. Science Advances, 2018, 4, eaau4580.	4.7	19
25	Chargeâ€mediated proteasome targeting. FASEB Journal, 2019, 33, 6852-6866.	0.2	19
26	Immunoproteasome enhances intracellular proteolysis of myelin basic protein. Doklady Biochemistry and Biophysics, 2013, 453, 300-303.	0.3	17
27	A kinase bioscavenger provides antibiotic resistance by extremely tight substrate binding. Science Advances, 2020, 6, eaaz9861.	4.7	17
28	Drift of the Subgingival Periodontal Microbiome during Chronic Periodontitis in Type 2 Diabetes Mellitus Patients. Pathogens, 2021, 10, 504.	1.2	16
29	Robotic QM/MM-driven maturation of antibody combining sites. Science Advances, 2016, 2, e1501695.	4.7	15
30	At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention. Cancers, 2021, 13, 4852.	1.7	15
31	Death Receptors: New Opportunities in Cancer Therapy. Acta Naturae, 2017, 9, 55-63.	1.7	15
32	Chemical Polysialylation and In Vivo Tetramerization Improve Pharmacokinetic Characteristics of Recombinant Human Butyrylcholinesterase-Based Bioscavengers. Acta Naturae, 2015, 7, 136-141.	1.7	14
33	Mediators and biomarkers of inflammation in meningitis: Cytokine and peptidome profiling of cerebrospinal fluid. Biochemistry (Moscow), 2016, 81, 1293-1302.	0.7	13
34	Multiscale computation delivers organophosphorus reactivity and stereoselectivity to immunoglobulin scavengers. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22841-22848.	3.3	13
35	Protective Allele for Multiple Sclerosis HLA-DRB1*01:01 Provides Kinetic Discrimination of Myelin and Exogenous Antigenic Peptides. Frontiers in Immunology, 2020, 10, 3088.	2.2	13
36	Chemical Polysialylation of Recombinant Human Proteins. Methods in Molecular Biology, 2015, 1321, 389-404.	0.4	11

#	Article	IF	CITATIONS
37	Protein PGLYRP1/Tag7 Peptides Decrease the Proinflammatory Response in Human Blood Cells and Mouse Model of Diffuse Alveolar Damage of Lung through Blockage of the TREM-1 and TNFR1 Receptors. International Journal of Molecular Sciences, 2021, 22, 11213.	1.8	11
38	Comprehensive Atlas of the Myelin Basic Protein Interaction Landscape. Biomolecules, 2021, 11, 1628.	1.8	11
39	Divergent Immunomodulation Capacity of Individual Myelin Peptidesâ€"Components of Liposomal Therapeutic against Multiple Sclerosis. Frontiers in Immunology, 2017, 8, 1335.	2.2	10
40	QM/MM Description of Newly Selected Catalytic Bioscavengers Against Organophosphorus Compounds Revealed Reactivation Stimulus Mediated by Histidine Residue in the Acyl-Binding Loop. Frontiers in Pharmacology, 2018, 9, 834.	1.6	10
41	Substrate specificity of catalytic autoantibodies in neurodegenerative processes. Doklady Biochemistry and Biophysics, 2007, 413, 61-64.	0.3	9
42	Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome. BioMed Research International, 2014, 2014, 1-10.	0.9	9
43	Salicylic acid influences the protease activity and posttranslation modifications of the secreted peptides in the moss <scp><i>Physcomitrella patens</i></scp> . Journal of Peptide Science, 2019, 25, e3138.	0.8	9
44	Suppression of ongoing experimental allergic encephalomyelitis in DA rats by novel peptide drug, structural part of human myelin basic protein 46–62. Autoimmunity, 2009, 42, 362-364.	1.2	8
45	Expression of catalytic antibodies in eukaryotic systems. Molecular Biology, 2011, 45, 74-81.	0.4	8
46	Antibody–antigen pair probed by combinatorial approach and rational design: Bringing together structural insights, directed evolution, and novel functionality. FEBS Letters, 2012, 586, 2966-2973.	1.3	8
47	Creation of catalytic antibodies metabolizing organophosphate compounds. Biochemistry (Moscow), 2012, 77, 1139-1146.	0.7	8
48	Autoantibodies from SLE patients induce programmed cell death in murine fibroblast cells through interaction with TNFR1 receptor. Scientific Reports, 2020, 10, 11144.	1.6	8
49	Stochastics of degradation: the autophagic-lysosomal system of the cell. Acta Naturae, 2020, 12, 18-32.	1.7	6
50	Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs. Biotechnology Letters, 2016, 38, 1173-1180.	1.1	5
51	Site-specific degradation of myelin basic protein by the proteasome. Doklady Biochemistry and Biophysics, 2009, 425, 68-72.	0.3	4
52	Extracellular HspBP1 inhibits formation of a cytotoxic Tag7–Hsp70 complex in vitro and in human serum. Biochimie, 2012, 94, 203-206.	1.3	4
53	Deimination of the myelin basic protein decelerates its proteasome-mediated metabolism. Doklady Biochemistry and Biophysics, 2016, 469, 277-280.	0.3	4
54	Modified siRNA effectively silence inducible immunoproteasome subunits in NSO cells. Biochimie, 2016, 125, 75-82.	1.3	4

#	Article	IF	Citations
55	Peptides Against Autoimmune Neurodegeneration. Current Medicinal Chemistry, 2017, 24, 1761-1771.	1.2	4
56	Diagnostics of autoimmune neurodegeneration using fluorescent probing. Scientific Reports, 2018, 8, 12679.	1.6	4
57	Probing Surface Membrane Receptors Using Engineered Bacteriophage Bioconjugates. Bioconjugate Chemistry, 2019, 30, 1500-1506.	1.8	4
58	Liquid drop of DNA libraries reveals total genome information. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27300-27306.	3.3	4
59	Exhaustive Search of the Receptor Ligands by the CyCLOPS (Cytometry Cell-Labeling Operable Phage) Tj ETQq1	1 0,78431 1.8	4 rgBT /Over
60	A New Precision Minimally Invasive Method of Glial Scar Simulation in the Rat Spinal Cord Using Cryoapplication. Frontiers in Surgery, 2021, 8, 607551.	0.6	4
61	In-depth characterization of ubiquitin turnover in mammalian cells by fluorescence tracking. Cell Chemical Biology, 2021, 28, 1192-1205.e9.	2.5	4
62	Deconvolution of the MBP-Bri2 Interaction by a Yeast Two Hybrid System and Synergy of the AlphaFold2 and High Ambiguity Driven Protein-Protein Docking. Crystals, 2022, 12, 197.	1.0	4
63	Polyamines Counteract Carbonate-Driven Proteasome Stalling in Alkaline Conditions. Biomolecules, 2020, 10, 1597.	1.8	3
64	Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting. Acta Naturae, 2015, 7, 74-79.	1.7	3
65	Cytokine profile as a marker of cell damage and immune dysfunction after spinal cord injury. Acta Naturae, 2020, 12, 92-101.	1.7	3
66	Expression of DNA-Encoded Antidote to Organophosphorus Toxins in the Methylotrophic Yeast Pichia Pastoris. Applied Biochemistry and Microbiology, 2016, 52, 162-169.	0.3	2
67	Heterodimer HLA-DM Fused with Constant Fragment of the Heavy Chain of the Human Immunoglobulin Accelerates Influenza Hemagglutinin HA306â€⁴318 Loading to HLA-DR1. Bulletin of Experimental Biology and Medicine, 2016, 161, 92-95.	0.3	2
68	Differential Diagnostics of Active Progressing Multiple Sclerosis Using a Fluorescent Biomarker with Resonance Energy Transfer. Bulletin of Experimental Biology and Medicine, 2019, 167, 329-334.	0.3	2
69	Loading Rate of Exogenous and Autoantigenic Determinants on Major Histocompatibility Complex Class II Mediates Resistance to Multiple Sclerosis. Doklady Biochemistry and Biophysics, 2019, 485, 115-118.	0.3	2
70	Control of Genome through Variative Nature of Histone-Modifying Ubiquitin Ligases. Biochemistry (Moscow), 2021, 86, S71-S95.	0.7	2
71	Excessive Labeling Technique Provides a Highly Sensitive Fluorescent Probe for Real-time Monitoring of Biodegradation of Biopolymer Pharmaceuticals in vivo. Acta Naturae, 2014, 6, 54-59.	1.7	2
72	Myelin-Reactive Monoclonal Antibodies from Multiple Sclerosis Patients Cross-React with Nucleoproteins in HEp-2 Lysate. BioNanoScience, 2016, 6, 322-324.	1.5	1

#	Article	lF	CITATIONS
73	mRNA expression profile of mouse oligodendrocytes in inflammatory conditions. Doklady Biochemistry and Biophysics, 2016, 469, 264-268.	0.3	1
74	Peptidyl Aldehyde Specifically Interacts with Immunosubunit $\hat{l}^21$ i Proteasome: In Vitro and In Vivo Effects. Bulletin of Experimental Biology and Medicine, 2016, 161, 69-71.	0.3	1
75	Analysis of Immunogenicity of Intracellular CTAR Fragments of Epstein—Barr Virus Latent Phase Protein LMP1. Bulletin of Experimental Biology and Medicine, 2017, 163, 766-771.	0.3	1
76	Evolution of catalytic centers of antibodies by virtual screening of broad repertoire of mutants using supercomputer. Doklady Biochemistry and Biophysics, 2017, 475, 245-249.	0.3	1
77	Combinatorial Screening of Peptides, Specific Ligands of Death Receptor DR5. Bulletin of Experimental Biology and Medicine, 2017, 163, 381-384.	0.3	1
78	High-Throughput Platform for B-Cell Screening Based on Fluorescent Phage-Display Technology. Bulletin of Experimental Biology and Medicine, 2019, 167, 446-451.	0.3	1
79	Topological Features of Histone H2A Monoubiquitination. Doklady Biochemistry and Biophysics, 2020, 493, 193-197.	0.3	1
80	Peculiarities of the Presentation of the Encephalitogenic MBP Peptide by HLA-DR Complexes Providing Protection and Predisposition to Multiple Sclerosis. Acta Naturae, 2021, 13, 127-133.	1.7	1
81	Clinical and experimental studies of multiple sclerosis in Russia: experience of the leading national research centers. Degenerative Neurological and Neuromuscular Disease, 2015, 5, 83.	0.7	O
82	Design of Chemical Conjugate for Targeted Therapy of Multiple Sclerosis Based of Constant Fragment of Human Antibody Heavy Chain and Peptoid Analog of Autoantigen MOG35-55. Bulletin of Experimental Biology and Medicine, 2017, 162, 777-780.	0.3	0